Transient neonatal diabetes mellitus caused by a gene mutation

Transient neonatal diabetes mellitus (TNDM) is a rare form of diabetes mellitus that presents within the first 6 months of life with remission in infancy or early childhood. TNDM is mainly caused by anomalies in the imprinted region on chromosome 6q24; however, recently, mutations in the ABCC8 gene,...

Full description

Saved in:
Bibliographic Details
Main Authors: Jung Hyun Kong (Author), June Bum Kim (Author)
Format: Book
Published: Korean Pediatric Society, 2011-04-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_e55e7df1c0ab4e4d9492e16d22ed7ffb
042 |a dc 
100 1 0 |a Jung Hyun Kong  |e author 
700 1 0 |a June Bum Kim  |e author 
245 0 0 |a Transient neonatal diabetes mellitus caused by a gene mutation 
260 |b Korean Pediatric Society,   |c 2011-04-01T00:00:00Z. 
500 |a 1738-1061 
500 |a 2092-7258 
500 |a 10.3345/kjp.2011.54.4.179 
520 |a Transient neonatal diabetes mellitus (TNDM) is a rare form of diabetes mellitus that presents within the first 6 months of life with remission in infancy or early childhood. TNDM is mainly caused by anomalies in the imprinted region on chromosome 6q24; however, recently, mutations in the ABCC8 gene, which encodes sulfonylurea receptor 1 (SUR1), have also been implicated in TNDM. Herein, we present the case of a male child with TNDM whose mutational analysis revealed a heterozygous c.3547C>T substitution in the ABCC8 gene, leading to an Arg1183Trp mutation in the SUR1 protein. The parents were clinically unaffected and did not show a mutation in the ABCC8 gene. This is the first case of a de novo ABCC8 gene mutation in a Korean patient with TNDM. The patient was initially treated with insulin and successfully switched to sulfonylurea therapy at 14 months of age. Remission of diabetes had occurred at the age of 16 months. Currently, the patient is 21 months old and is euglycemic without any insulin or oral hypoglycemic agents. His growth and physical development are normal, and there are no delays in achieving neurological and developmental milestones. 
546 |a EN 
690 |a Diabetes mellitus 
690 |a Infant 
690 |a Sulfonylurea receptor 
690 |a Mutation 
690 |a Pediatrics 
690 |a RJ1-570 
655 7 |a article  |2 local 
786 0 |n Korean Journal of Pediatrics, Vol 54, Iss 4, Pp 179-182 (2011) 
787 0 |n http://kjp.or.kr/upload/pdf/kjped-54-179.pdf 
787 0 |n https://doaj.org/toc/1738-1061 
787 0 |n https://doaj.org/toc/2092-7258 
856 4 1 |u https://doaj.org/article/e55e7df1c0ab4e4d9492e16d22ed7ffb  |z Connect to this object online.